|
Klinik für Innere Medizin III, Klinikum der Friedrich-Schiller-Universität Jena, Jena. martin.busch@med.uni-jena.de BACKGROUND: Membranous nephropathy (MN) is characterized by proteinuria and other symptoms of the nephrotic syndrome. In many cases, the etiology is unknown. Whether and how to treat MN is still a controversial question. Despite the use of corticosteroids and alkylating agents, up to 40% of patients still progress to end-stage renal failure. CASE REPORT: A 40-year-old male patient with biopsy-proven idiopathic MN was initially treated with prednisolone and chlorambucil because of a proteinuria of 22 g/d. Treatment with cyclosporine was started because the nephrotic syndrome failed to improve. Proteinuria was reduced to a minimum of 4 g/d. Cyclosporine was stopped after 17 months leading to a fast relapse. Therapy with an ACE inhibitor and AT(1) receptor antagonist and retreatment with cyclosporine improved proteinuria. Cyclosporine was terminated after a total of 24 ...
more
|
Is the anti-CD20 antibody rituximab a reasonable option?
Related Questions
- Rituximab is given as an injection through a needle placed into a vein. The medicine must be given slowly ...
- Rituximab is an experimental drug for antiphospholipid syndrome. We are asking this question right now in our ...
- Response rates to rituximab in refractory ITP range between 30-60% with sustained responses in the 20-30% ...
- PGxPredict:RITUXIMAB test is a pharmacogenetic test that will provide information on whether a patient is ...
- Many medications can cause side effects. A side effect is an unwanted response to a medication when it is ...